Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02279004 · ClinicalTrials.gov registry record
A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care
A clinical trial of Melanoma and NSCLC, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- 840
- Enrollment target
- 1
- Study location
NCT02279004 is a study of Melanoma and NSCLC that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 840 participants, above the 703-participant average among 266 other Melanoma trials with a reported enrollment target (19% higher). The trial reports 1 study location across 1 state.
The verdict
NCT02279004, a study of Melanoma and NSCLC, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- 840 participants
- Enrollment target
- 1
- Study location
Study Summary
Tumor genotyping has become an essential biomarker for the care of advanced lung cancer and melanoma, and is currently used to identify patients for treatment with targeted kinase inhibitors like erlotinib and vemurafenib. However, tumor genotyping can be slow and cumbersome, and is limited by availability of tumor biopsy tissue for testing. The aim of this study is to prospectively evaluate a blood-based genotyping tool that can quantify the presence of oncogenic mutations (EGFR, KRAS, BRAF) in patients with lung cancer and melanoma. This assay is being studied both as a diagnostic tool for classifying patient genotype, and a serial measurement tool for quantification of response and progression on therapy.
Study Locations (1)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 840 participants |
| Start Date | 2014-07-03 |
| Est. Completion | 2026-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02279004
The ClinicalTrials.gov registry entry for NCT02279004 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 840 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 703-participant average among 266 other Melanoma trials with a reported enrollment target (19% higher). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Melanoma appearing as the primary indexed condition, and to 0 interventions.
NCT02279004 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02279004 about?
NCT02279004 is a clinical study titled "A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care". Tumor genotyping has become an essential biomarker for the care of advanced lung cancer and melanoma, and is currently used to identify patients for treatment with targeted kinase inhibitors like erlotinib and vemurafenib. However, tumor genotyping can be slow and cumbersome, and is limited by avail...
What is the current status of trial NCT02279004?
This trial is currently recruiting. The enrollment target is 840 participants. The study started on 2014-07-03. Estimated completion is 2026-12.
What conditions does trial NCT02279004 study?
This clinical trial studies the following conditions: Melanoma, NSCLC.
Who is sponsoring clinical trial NCT02279004?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02279004 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
RECRUITING · NA
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Dabrafenib and/or Trametinib Rollover Study
RECRUITING · Phase 4
-
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RECRUITING · Phase 2
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.